ocriplasmin (Jetrea)

‘Real-world’ ocriplasmin macular hole closure rates lag trialsOcriplasmin (Jetrea, ThromboGenics) may achieve lower macular hole closure rates than in trials, new British and Irish data suggests. Also, “the incidence of adverse events was greater than previously reported,” wrote RJ Haynes of Bristol Eye Hospital in Bristol, United Kingdom, and colleagues in the journal Eye.
Real-world experience provides new insights on ocriplasmin
Real-world experience provides new insights on ocriplasminReal-world experience with ocriplasmin (Jetrea, ThromboGenics) show that the treatment success rate can be increased by appropriate patient selection.
Ocriplasmin gains first Asian approval in MalaysiaThromboGenics’ ocriplasmin (Jetrea) as been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT).
ThromboGenics to expand VMA, DME researchThromboGenics has taken steps to expand its research of treatments for vitreomacular adhesion (VMA) and diabetic macular edema (DME).